S Romberger

[S Romberger @susanfoofoo]

$RIOT Riot Platforms price target raised to $40 from $25 at H.C. Wainwright

[TipRanks @TipRanks]

Analysts turned sharply more bullish on Riot Platforms $RIOT following its Q2 update, with the company’s data center expansion becoming the central focus.

The key catalyst was Riot’s $9.1 billion, 20-year data center lease with a leading frontier AI lab for 191 MW of critical IT capacity at its Rockdale campus. Piper Sandler highlighted the deal as a major validation of Riot’s data center strategy, with 96 IT MW expected to come online by December 2027 and the remaining 95 IT MW by June 2028.

Citi called the quarter “transformational,” raising its price target to $32 from $28 and maintaining a Buy rating. The firm believes Riot is building one of the most compelling contracted data center platforms in the sector. H.C. Wainwright was even more bullish, raising its target to $40 from $25 after pointing to both the new large-scale AI contract and tangible leasing progress at Riot’s Corsicana campus.

Piper Sandler raised its target to $25 from $23 and maintained Overweight.

Overall, analysts increasingly see RIOT evolving beyond bitcoin mining into a large-scale AI and data center infrastructure story – with long-duration contracted revenue and additional leasing opportunities providing the biggest upside catalysts.

[Aditya R @AdityaInvests90]

$NBIS whales are now buying $380 calls….

This is almost $200 or 100% out the money currently

If these hit we still have insane upside left for this year

[Finsee @Finsee_main]

$FET Q2 2026 earnings: Stellar Execution Drives Massive Operating Leverage

Forum Energy Technologies (FET) delivered a definitive beat-and-raise quarter, proving its 'Beat the Market' strategy is working. Revenue is Accelerating, growing 8% sequentially to $226 million despite a stagnant global rig count. The real story, however, is on the bottom line. Adjusted EBITDA surged 39% sequentially to $32 million as the company extracted significant operating leverage from facility consolidations and improved product mix. Management confidently raised full-year 2026 guidance across all metrics, projecting a clear path toward its ambitious 'FET 2030' strategic vision.

Full article with charts - link in bio

🐂 𝐁𝐮𝐥𝐥 𝐂𝐚𝐬𝐞
• 𝐌𝐚𝐫𝐠𝐢𝐧 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐢𝐬 𝐒𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐚𝐥 — The 300 basis point sequential expansion in Adjusted EBITDA margin reflects permanent structural improvements, notably the consolidation of manufacturing plants. This positions FET to capture outsized incremental margins as volumes grow.
• 𝐒𝐡𝐚𝐫𝐞 𝐆𝐚𝐢𝐧𝐬 𝐎𝐮𝐭𝐩𝐚𝐜𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐲𝐜𝐥𝐞 — A 104% book-to-bill ratio and 13% sequential market share gain demonstrate that FET's product innovation and international expansion are successfully decoupling its growth from flat U. S. rig activity.

🐻 𝐁𝐞𝐚𝐫 𝐂𝐚𝐬𝐞
• 𝐌𝐚𝐜𝐫𝐨 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐑𝐞𝐦𝐚𝐢𝐧𝐬 𝐌𝐮𝐭𝐞𝐝 — The company's raised guidance relies on out-executing a flat market. If the global rig count deteriorates further, customer pushouts could threaten the back-half growth assumptions.
• 𝐒𝐮𝐛𝐬𝐞𝐚 𝐁𝐚𝐜𝐤𝐥𝐨𝐠 𝐌𝐚𝐫𝐠𝐢𝐧 𝐃𝐫𝐚𝐠 — While the subsea backlog provides excellent revenue visibility, it contains a high percentage of pass-through items that carry lower contribution margins, capping the ultimate gross margin ceiling.

⚖️ 𝐕𝐞𝐫𝐝𝐢𝐜𝐭: 🟢
Bullish. The company is actively proving it can grow earnings exponentially faster than revenue in a sideways market. With net leverage dropping to 1.1x and full-year free cash flow guidance raised to $57-$77M, FET has a strong hand to execute aggressive share repurchases or M&A.

𝐊𝐞𝐲 𝐓𝐡𝐞𝐦𝐞𝐬

🟢 𝐅𝐚𝐜𝐢𝐥𝐢𝐭𝐲 𝐂𝐨𝐧𝐬𝐨𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐌𝐚𝐫𝐠𝐢𝐧 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 [NEW]
The structural cost savings program is Accelerating results. The Drilling and Completions segment achieved an Adjusted EBITDA margin of 11.9%, up from 10.1% last quarter. Management explicitly cited 'improved plant utilization related to facility consolidation' as the catalyst. This proves that the operational restructuring executed in prior quarters is now generating tangible, sustainable operating leverage.

🟢 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐡𝐚𝐫𝐞 𝐆𝐚𝐢𝐧𝐬 𝐯𝐢𝐚 '𝐁𝐞𝐚𝐭 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭' 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲
FET is aggressively taking market share. Despite an uninspiring macro environment, revenue per rig is Accelerating, climbing to $129 globally from $114 in Q1 2026. Management noted a 13% sequential increase in market share. The ability to outgrow the underlying global rig count validates the commercial focus on penetrating 'Growth Markets' rather than relying entirely on industry upcycles.

🟢🟢 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐒𝐮𝐛𝐬𝐞𝐚 𝐚𝐧𝐝 𝐀𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐨𝐧
Product innovation remains the primary growth engine. The Drilling and Completions segment secured a 104% book-to-bill ratio driven by aftermarket ROV upgrades in the Subsea product line. Additionally, demand for specialized capital equipment like automated iron roughnecks and radiators is fueling top-line growth and expanding the company's addressable technology footprint.

🔴 𝐃𝐞𝐥𝐚𝐲𝐞𝐝 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐄𝐪𝐮𝐢𝐩𝐦𝐞𝐧𝐭 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐢𝐞𝐬 [NEW]
While Artificial Lift and Downhole segment revenue grew 6%, management explicitly noted that this was 'partially offsetting the increase was delayed production equipment deliveries.' This is a critical data point indicating that customer scheduling or supply chain friction is capping near-term revenue realization in a segment that just posted a stellar 24.8% Adjusted EBITDA margin.

🔴 𝐒𝐮𝐛𝐬𝐞𝐚 𝐁𝐚𝐜𝐤𝐥𝐨𝐠 𝐌𝐢𝐱 𝐃𝐫𝐚𝐠
The mix of the backlog requires close monitoring. While Subsea orders are robust, historical commentary from management confirms these projects often carry lower contribution margins due to high volumes of 'pass-through' materials. As these large projects convert to revenue in the second half of 2026, they could create downward pressure on consolidated gross margins despite the positive volume variance.

⚪ 𝐌𝐚𝐜𝐫𝐨 𝐑𝐢𝐬𝐤: 𝐅𝐥𝐚𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐬𝐬𝐮𝐦𝐩𝐭𝐢𝐨𝐧
The entire bullish narrative rests on a macro assumption that global drilling activity remains 'flat'. While FET is successfully gaining share, the average global rig count actually declined to 1,759 in Q2 from 1,832 in Q1. If international or U. S. operator budgets contract further, overcoming the sheer gravity of a shrinking TAM will become exponentially more difficult, turning their raised guidance into a liability.

𝐎𝐭𝐡𝐞𝐫 𝐊𝐏𝐈𝐬

𝐅𝐫𝐞𝐞 𝐂𝐚𝐬𝐡 𝐅𝐥𝐨𝐰: $9.65 million
Reversing the seasonal weakness seen in Q1 ($1.37M). This sequential rebound allowed the company to execute share repurchases while continuing to deleverage. First half 2026 free cash flow stands at $11.0M, requiring a significant working capital release in the second half to hit the $57-$77M full-year target.

𝐍𝐞𝐭 𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐞 𝐑𝐚𝐭𝐢𝐨: 1.1x
Accelerating improvement. Net leverage dropped to 1.1x from 1.4x in Q1 2026, driven by the surge in Trailing Twelve Months Adjusted EBITDA ($100.4M vs $89.2M in Q1). The company is rapidly approaching its stated target of <1.0x, giving management ultimate flexibility between aggressive buybacks and M&A.

𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞

𝐐𝟑 𝟐𝟎𝟐𝟔 𝐑𝐞𝐯𝐞𝐧𝐮𝐞: $225 - $245 million
Stable. The $235 million midpoint represents a modest 4% sequential increase from Q2 2026, but implies an impressive 20% YoY growth compared to Q3 2025. This indicates a high level of confidence in converting the existing backlog.

𝐐𝟑 𝟐𝟎𝟐𝟔 𝐀𝐝𝐣𝐮𝐬𝐭𝐞𝐝 𝐄𝐁𝐈𝐓𝐃𝐀: $31 - $37 million
Accelerating. The $34 million midpoint represents a 48% YoY surge. Operating margins are expected to hold steady or expand slightly from Q2 levels, validating that Q2's profitability step-function was not a one-off anomaly.

𝐅𝐘 𝟐𝟎𝟐𝟔 𝐑𝐞𝐯𝐞𝐧𝐮𝐞: $870 - $910 million
Accelerating. Raised by 6% from prior guidance. The new $890 million midpoint implies a 13% YoY growth rate over FY 2025. Achieving this will require an average of roughly $232 million in revenue per quarter for the back half of the year, perfectly aligned with the Q3 guide.

𝐅𝐘 𝟐𝟎𝟐𝟔 𝐀𝐝𝐣𝐮𝐬𝐭𝐞𝐝 𝐄𝐁𝐈𝐓𝐃𝐀: $115 - $125 million
Accelerating. Management raised the full-year target by 17% over prior guidance. The midpoint implies 40% YoY growth, drastically outpacing the 13% expected revenue growth. This massive operating leverage is the core driver of the current bull thesis.

𝐊𝐞𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬

𝐀𝐋&𝐃 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐃𝐞𝐥𝐚𝐲𝐬
You noted delayed production equipment deliveries capped AL&D growth this quarter. Are these delays driven by customer pushouts or internal supply chain constraints, and have they already begun converting to revenue in Q3?

𝐒𝐮𝐛𝐬𝐞𝐚 𝐁𝐚𝐜𝐤𝐥𝐨𝐠 𝐂𝐨𝐦𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧
Given the strong Subsea aftermarket ROV orders, what is the current margin profile of the Subsea backlog compared to six months ago? Are we moving past the lower-margin 'pass-through' heavy phase?

𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐀𝐥𝐥𝐨𝐜𝐚𝐭𝐢𝐨𝐧 𝐓𝐢𝐩𝐩𝐢𝐧𝐠 𝐏𝐨𝐢𝐧𝐭
With Net Leverage now down to 1.1x and the stock reacting to massive earnings beats, how does the calculus between executing the remaining share repurchase authorization and pursuing M&A shift heading into the second half of 2026?

[S Romberger @susanfoofoo]

$QBTS consensus price target $34.67 even before today's news
https://t.co/WnD1JzCuZ8

[Hardik Shah @AIStockSavvy]

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $QBTS D-Wave Signs LOI for $𝟏𝟎𝟎𝐌 U.S. CHIPS Act Funding

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ D-Wave signs LOI for proposed $𝟏𝟎𝟎𝐌 funding under the 𝐂𝐇𝐈𝐏𝐒 𝐀𝐜𝐭.

➤ U.S. Department of Commerce to receive $𝟏𝟎𝟎𝐌 in D-Wave equity shares.

➤ Funding supports 𝐚𝐧𝐧𝐞𝐚𝐥𝐢𝐧𝐠 and 𝐠𝐚𝐭𝐞-𝐦𝐨𝐝𝐞𝐥 quantum technology development.

➤ D-Wave plans advanced R&D expansion in 𝐅𝐥𝐨𝐫𝐢𝐝𝐚, Connecticut, and Canada.

➤ Company targets delivery of a 𝟏𝟎𝟎,𝟎𝟎𝟎-𝐪𝐮𝐛𝐢𝐭 annealing system.

➤ Also advancing a 𝟏𝟎,𝟎𝟎𝟎-𝐪𝐮𝐛𝐢𝐭 𝐠𝐚𝐭𝐞-𝐦𝐨𝐝𝐞𝐥 quantum computer.

➤ Investment aims to strengthen 𝐔.𝐒. 𝐪𝐮𝐚𝐧𝐭𝐮𝐦 leadership and domestic supply chains.

[Seeking Alpha @SeekingAlpha]

ServiceNow $NOW is capturing Wall Street's attention today as Bank of America initiates coverage with a Buy rating and a $130 price target.

The Bull Case:

Analyst Tal Liani argues ServiceNow will benefit from—not be replaced by—the autonomous agentic AI cycle.

Displacing its deeply entrenched workflow system would be incredibly complex and costly for enterprises.

cRPO growth has exceeded 20% for 5 consecutive quarters, showcasing heavy platform demand.

BofA projects strong revenue growth of 18% to 22% through 2028, with FCF margins stretching to 37%.

While some investors are nervous about AI disrupting classic SaaS, BofA is betting that ServiceNow’s footprint will make it the ultimate "AI Control Tower" for the enterprise.

[S Romberger @susanfoofoo]

$LMRI up after hours. Consensus price target $19
https://t.co/BnyVkFFcfc

[InsiderBaba @insiderbaba]

🟢 Insider Buy: $LMRI
H. Cooper bought $223K · @ $7.44 · +100% increased · May 14

🔗 https://t.co/NjDy5zaXUN

[S Romberger @susanfoofoo]

$ALHC average price target $23.11
https://t.co/jYHVk1rqA4

[Open Outcrier @OpenOutcrier]

$ALHC (+4.9% pre) Alignment Healthcare Set to Join S&amp;P SmallCap 600

https://t.co/8BVwcExFBi

[S Romberger @susanfoofoo]

$QUBT consensus price target $17.50
https://t.co/U1Y7azkeu2

[Masaru Trades @masarutrades]

Quantum Computing $QUBT

Quantum Computing shares up big today after first quarter revenue explodes 9,000%.

The company also ended the quarter with $1.4 billion in cash and equivalents and a backlog of $16 million.

[S Romberger @susanfoofoo]

$INOD price target $100?
https://t.co/8wve0vZAHE

[alldaystocks | 24/7 Market News @allday_stocks]

$INOD 𝐈𝐧𝐧𝐨𝐝𝐚𝐭𝐚: 𝐑𝐞𝐜𝐨𝐫𝐝 𝐐𝟏, 𝐑𝐚𝐢𝐬𝐞𝐬 𝟐𝟎𝟐𝟔 𝐆𝐫𝐨𝐰𝐭𝐡 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 𝐓𝐨 𝟒𝟎%+

📊 𝐑𝐞𝐬𝐮𝐥𝐭𝐬
• Revenue: $90.1M (+54% YoY)
• Adjusted EBITDA: $25.0M (+96% YoY)
• Adjusted gross margin: 47%
• Net income: $14.9M
• Cash & investments: $117.4M
⠀
🎯 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞
• FY26 revenue growth raised to ~40%+ (from ~35%+)
• New Big Tech engagements expected to generate ~$51M revenue in 2026
⠀
📌 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬
• Revenue beat consensus by 18%
• Adjusted EBITDA beat consensus by 139%
• Revenue from other Big Tech customers grew 453% YoY
• Launched Evaluation & Observability Platform beta for agentic AI systems
• Closed initial $1M hyperscaler platform engagement
⠀
💬 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐞𝐧𝐭𝐚𝐫𝐲
“We believe Innodata is entering a golden age of innovation.”

[S Romberger @susanfoofoo]

$VRDN consensus price target $37.07
https://t.co/zI5nindGe0

[Bio Stocks™ @BioStocks]

$VRDN Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect -

[zohm @zohmbastic]

$HRMY
Oppenheimer analyst Jay Olson raised the firm's price target on Harmony Biosciences to $72 from $62 and keeps an Outperform rating on the shares. The firm attributes yesterday's share rally to Harmony's recent patent litigation defending Wakix, which it believes "helped dispel bears" that expected loss of exclusivity before 2030. Harmony has always appeared well positioned to defend the Wakix intellectual property, the analyst tells investors in a research note.

[S Romberger @susanfoofoo]

$ONDS consensus price target $17.25
https://t.co/uVQng1igfU

[VBonk @Allstarsv16]

$ONDS today gained +7.3%. The Company is one of the most fundamentally compelling autonomous drone stock in the public markets right now.

Revenue and growth
FY2024 revenue: $7.2 million.
FY2025 revenue: $50.7 million.
That is 605% year-over-year growth.

Q4 2025 alone: $30.1 million, up 629% YoY.

Q1 2026 target: $38-40 million, representing 820% YoY growth.
Full-year 2026 target: at least $375 million. Nearly 7x from 2025 in a single year.

This is not a growth stock. This is a compounding machine.

Gross margin
But revenue without margins is noise.

Gross margin in 2024: 5%.
Gross margin in 2025: 40%.
That 35 point expansion in 12 months is the signature of a business that has crossed the industrialization threshold.

Balance sheet
The balance sheet, because in defense tech, capital is oxygen.

Cash at Dec 31, 2025: $594 million. January 2026 raise: $960 million net proceeds.

Pro forma cash entering 2026: approximately $1.55 billion. Ondas is not surviving. It is hunting.

M&A strategy
The M&A strategy is where the thesis becomes structural.

Since July 2025, Ondas has executed 10+ acquisitions building a vertically integrated system-of-systems platform: Sentrycs ($224.6M) for cyber counter-UAS, Roboteam ($81.7M) for tactical ground robotics, Mistral ($175M) for U.S. prime contractor status and $1B+ in Army and SOCOM IDIQ access, Rotron Aerospace ($39.9M) for long-range propulsion, Bird Aerospace ($110M) for advanced aerial platforms, and 4M Defense for autonomous demining.

Each acquisition is a capability node. Together they form a stack no competitor has assembled at this speed.

Palantir partnership
The Palantir partnership is the AI layer that ties it all together.

Ondas is integrating Palantir AIP (Warp Speed, Foundry, Maven) across its command and control architecture, spanning aerial ISR, ground robotics, and now stratospheric sensing through the recently completed World View acquisition.

This is not a press release. This is the blueprint for next-generation multi-domain defense.

Last contracts signed
Now the contract wins, because in 2026 alone the pipeline has been relentless.

February 3: Airobotics secures a strategic multi-phase autonomous UAS defense contract in Asia-Pacific.

February 9: 4M Defense wins a $30 million demining program in Israel along the Syria border.

February 17: Sentrycs wins a German State Police counter UAS contract in a $9.8 billion TAM market.

March 4: Airobotics receives a $20 million initial order as prime contractor to deploy thousands of drones for a national autonomous border protection program.

April 6: 4M Defense wins a second tender tied to Israel's $1.7 billion Eastern Border Security Barrier, with expected value exceeding $50 million and potential for hundreds of millions in follow-on.

April 7: Sentrycs wins multi-million dollar contracts to secure airspace at the 2026 FIFA World Cup across 16 cities in the U.S., Canada, and Mexico.

April 20: $10 million initial order formally launches large-scale demining operations along Israel's eastern border.

The company is now simultaneously operational in Israel, Germany, Asia-Pacific, and across North America. That is what a global defense prime looks like in year one.

Risks
Risks exist. Dilution has been significant, share count went from 93 million to 381 million in 12 months.

Profitability is guided at the product level in Q3 2026, OAS-level in Q3 2027, and company-wide in Q1 2028. This is a long-duration bet on execution.

But if you are looking for the single public company with the capital, the technology stack, the government contracting access, the Palantir-grade AI infrastructure, and the revenue trajectory to define autonomous defense in 2030, the answer is $ONDS.

Everything else is a point solution. Ondas is building the platform.

Not financial advice. Do your own due diligence.

$AVAV $AVEX $KTOS $REDW $SPAI $UMAC $PLTR $JOBY $ACHR $AGH $PDW

[S Romberger @susanfoofoo]

$BBOT consensus price target $26
https://t.co/Iz7v8RrAhE

[S Romberger @susanfoofoo]

$NKTR Nektar price target raised to $185 from $165 at H.C. Wainwright

[Ben Fidler @BentheFidler]

Nektar surges again as alopecia drug shows new promise in extension study https://t.co/UV0ccY4HiR @ByJonGardner $NKTR + 25% $LLY

[S Romberger @susanfoofoo]

$NBIS
Nebius price target raised to $175 from $150 at BofA

[Michael Burry Stock Tracker ♟ @burrytracker]

Pour one out for $NBIS investors

Jim Cramer: "I wouldn't short or sell this one though"

[S Romberger @susanfoofoo]

$PR Permian Resources initiated with a Buy at Truist
Truist. $24 price target.

[S Romberger @susanfoofoo]

$BETA consensus price target $36.56
https://t.co/pDWqnvq5re

[MiloX Trading @CryptoMilox]

Amazon $AMZN disclosed new positions in $BETA and exited $SMRT, $OWLT, and $VITL. @grok

[S Romberger @susanfoofoo]

$LRN
Barrington Research analyst Alexander Paris maintains Stride with a Outperform and maintains $125 price target.

[S Romberger @susanfoofoo]

$IBRX consensus price target $11.50
https://t.co/qG3WCjscRp

[Carter Vance📚 ⭐ @carter_van_bot]

🚨 $IBRX surges to $5.17 +30.76% on pivotal clinical catalyst.

1️⃣ Product-market fit validated with durable complete response data.

2️⃣ Chemotherapy-free CAR-NK therapy demonstrates 15-month efficacy in Waldenstrom Lymphoma.

💭

[S Romberger @susanfoofoo]

$AUTL consensus price target $8.67
https://t.co/7HqQzzhUBa

[NOTRELOAD AI @notreload_ai]

$AUTL +8.7% [Needham boosts Autolus Therapeutics price target to $11, keeps Buy rating, and highlights breakeven potential and upside from obe-cel and Aucatzyl.] https://t.co/dx5ofYs76U